Cardiol Therapeutics (TSX:CRDL) Total Assets : C$31.13 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Cardiol Therapeutics Total Assets?

Cardiol Therapeutics's Total Assets for the quarter that ended in Mar. 2024 was C$31.13 Mil.

During the past 12 months, Cardiol Therapeutics's average Total Assets Growth Rate was -20.60% per year. During the past 3 years, the average Total Assets Growth Rate was -1.80% per year. During the past 5 years, the average Total Assets Growth Rate was -25.70% per year.

During the past 7 years, Cardiol Therapeutics's highest 3-Year average Total Assets Growth Rate was 29.30%. The lowest was -33.10%. And the median was -11.20%.

Total Assets is connected with ROA %. Cardiol Therapeutics's annualized ROA % for the quarter that ended in Mar. 2024 was -108.28%. Total Assets is also linked to Revenue through Asset Turnover. Cardiol Therapeutics's Asset Turnover for the quarter that ended in Mar. 2024 was 0.00.

Cardiol Therapeutics Total Assets Historical Data

The historical data trend for Cardiol Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardiol Therapeutics Total Assets Chart

Cardiol Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

15.50

15.89

87.88

62.03

36.70

Cardiol Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Assets	Get a 7-Day Free Trial															52.69	47.17	43.05	36.70	31.13

Cardiol Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Cardiol Therapeutics's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	28.247	+	8.454
	=	36.70

Cardiol Therapeutics's Total Assets for the quarter that ended in Mar. 2024 is calculated as

Total Assets	=	Total Equity (Q: Mar. 2024 )	+	Total Liabilities (Q: Mar. 2024 )
	=	20.059	+	11.067
	=	31.13

Cardiol Therapeutics (TSX:CRDL) Total Assets Explanation

Total Assets is connected with ROA %.

Cardiol Therapeutics's annualized ROA % for the quarter that ended in Mar. 2024 is

ROA %	=	Net Income (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	-36.72	/	( (36.701	+	31.126)	/ 2 )
	=	-36.72	/	33.9135
	=	-108.28 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Cardiol Therapeutics's Asset Turnover for the quarter that ended in Mar. 2024 is

	Asset Turnover
=	Revenue (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
=	0	/	( (36.701	+	31.126)	/ 2 )
=	0	/	33.9135
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Cardiol Therapeutics Total Assets Related Terms

Thank you for viewing the detailed overview of Cardiol Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Cardiol Therapeutics (TSX:CRDL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cardiol Therapeutics Inc (TSX:CRDL) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

CRDL:USA CT9:Germany

Address

2265 Upper Middle Road East, Suite 602, Oakville, ON, CAN, L6H 0G5

Website

https://www.cardiolrx.com

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

Executives

Guillermo Torre

Senior Officer